Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer

Launched by XINQIAO HOSPITAL OF CHONGQING · Feb 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether thalidomide can improve the effectiveness of a combination treatment using cetuximab and standard chemotherapy for patients with stage IV left colorectal cancer that cannot be surgically removed. The researchers hope to find out if adding thalidomide helps the treatments work better and to understand how certain chemicals in the body, called cytokines, may affect treatment outcomes. This study is important because it could lead to more effective therapies for this type of cancer.

To participate in this trial, patients must be between 18 and 75 years old and have a specific type of colorectal cancer confirmed by medical tests. They should be in relatively good health, with no serious organ problems and should not have received previous chemotherapy or cetuximab. Participants will receive treatment and be monitored by the study team, and they will need to provide informed consent to take part. This trial is currently recruiting participants, and those interested should discuss it with their healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue/cytology and genetic testing;
• • 2. Physical state is good: PS 0-2;
• • 3. Expected survival of more than 3 months;
• • 4. Aged 18-75 years old;
• • 5. Have not received systematic chemotherapy before;
• • 6. Did not receive cetuximab treatment;
• • 7. Liver, kidney and bone marrow functions are basically normal;
• • 8. The clearance period of chemotherapy and molecular targeted therapy is more than 4 weeks;
• • 9. Voluntary participation in the group, good compliance, can cooperate with the experiment observation, and sign the written informed consent.
• Exclusion Criteria:
• • 1. Patients with severe dysfunction of vital organs (heart, liver, kidney);
• • 2. Patients with other malignant tumors;
• • 3. Patients who are pregnant or breastfeeding (women of childbearing age need to check pregnancy test);
• • 4. In the active phase of acute or chronic infectious diseases;
• • 5. People with a clear history of drug allergy or allergic constitution;
• • 6. Patients participating in other clinical trials;
• • 7. Other conditions in which the patient was considered inappropriate to participate in the study.